Search in:

Expert Review of Neurotherapeutics Volume 15, 2015 - Issue 12

Submit an article Journal homepage

351

Views

CrossRef citations to date

Altmetric

Drug profiles

The efficacy of oral adenosine A_2A antagonist istradefylline for the treatment of moderate to severe Parkinson’s disease

Ruxandra Julia VorovenciUniversity of Medicine and Pharmacy “Victor Babes”; County Hospital, Department of Neurology, Timisoara, Romania;Parkinson and Movement Disorders Unit, IRCCS Hospital San Camillo, Venice, Italy

Angelo AntoniniParkinson and Movement Disorders Unit, IRCCS Hospital San Camillo, Venice, ItalyCorrespondence[email protected]

Pages 1383-1390 | Published online: 02 Dec 2015

Cite this article
https://doi.org/10.1586/14737175.2015.1113131
CrossMark

Full Article
Figures & data
References
Citations
Metrics
Reprints & Permissions

References

Papers of special note have been highlighted as:
Google Scholar
* of interest
Google Scholar
** of considerable interest
Google Scholar
Jenner P. Istradefylline, a novel adenosine A2A receptor antagonist, for the treatment of Parkinson’s disease. Expert Opin Investig Drugs. 2005;14(6):729–738.
PubMed Web of Science ®Google Scholar
Kalia LV, Brotchie JM, Fox SH. Novel nondopaminergic targets for motor features of Parkinson’s disease: review of recent trials. Mov Disord. 2013;28(2):131–144.
PubMed Web of Science ®Google Scholar
Antonini A, Poewe W. Adenosine A2A receptor antagonists in Parkinson’s disease: still in the running. Lancet Neurol. 2014;13(8):748–749.
PubMed Web of Science ®Google Scholar

*Synopsis: A phase 2 trial on the A2A receptor antagonist tozadenant shows similar efficacy as istradefylline and preladenant.

LeWitt PA, Guttman M, Tetrud JW, et al. Adenosine A2A receptor antagonist istradefylline (KW-6002) reduces “off” time in Parkinson’s disease: a double-blind, randomized, multicenter clinical trial (6002-US-005). Ann Neurol. 2008;63(3):295–302.
PubMed Web of Science ®Google Scholar

*Synopsis: The promising A2A receptor antagonist istradefylline was well tolerated and proven safe, and provided a clinically meaningful reduction of off-time in patients with advanced PD.

Rosin DL, Hettinger BD, Lee A, et al. Anatomy of adenosine A2A receptors in brain: morphological substrates for integration of striatal function. Neurology. 2003;61(11 Suppl 6):S12–S18.
PubMedGoogle Scholar
Fernandez HH, Greeley DR, Zweig RM, et al. Istradefylline as monotherapy for Parkinson disease: results of the 6002-US-051 trial. Parkinsonism Relat Disord. 2010;16(1):16–20.
PubMed Web of Science ®Google Scholar

*Synopsis: Istradefylline as monotherapy for PD was proven safe and well tolerated, while statistical significance in improving motor control lacked in this study.

Hauser RA, Shulman LM, Trugman JM, et al. Study of istradefylline in patients with Parkinson’s disease on levodopa with motor fluctuations. Mov Disord. 2008;23(15):2177–2185.
PubMed Web of Science ®Google Scholar

*Synopsis: Istradefylline as add-on therapy to a stable levodopa regimen significantly reduced the off-time in advanced stages of PD, while it is safe and well tolerated.

Ochi M, Shiozaki S, Kase H. Adenosine A2A receptor-mediated modulation of GABA and glutamate release in the output regions of the basal ganglia in a rodent model of Parkinson’s disease. Neuroscience. 2004;127(1):223–231.
PubMed Web of Science ®Google Scholar
Svenningsson P, Hall H, Sedvall G, et al. Distribution of adenosine receptors in the postmortem human brain: an extended autoradiographic study. Synapse. 1997;27(4):322–335.
PubMed Web of Science ®Google Scholar
Mishina M, Ishiwata K, et al. Adenosine A(2A) receptors measured with [C]TMSX PET in the striata of Parkinson’s disease patients. PLoS One. 2011;6(2):e17338.
PubMed Web of Science ®Google Scholar
Barret O, Hannestad J, Vala C, et al. Characterization in humans of 18F-MNI-444, a PET radiotracer for brain adenosine 2A receptors. J Nucl Med. 2015;56(4):586–591.
PubMed Web of Science ®Google Scholar
Rodriguez-Oroz MC, Jahanshahi M, Krack P, et al. Initial clinical manifestations of Parkinson’s disease: features and pathophysiological mechanisms. Lancet Neurol. 2009;8(12):1128–1139.
PubMed Web of Science ®Google Scholar
Hauser RA. Future treatments for Parkinson’s disease: surfing the PD pipeline. Int J Neurosci. 2011;121(Suppl 2):53–62.
PubMed Web of Science ®Google Scholar
Mizuno Y, Kondo T. Adenosine A2A receptor antagonist istradefylline reduces daily OFF time in Parkinson’s disease. Mov Disord. 2013;28(8):1138–1141.
PubMed Web of Science ®Google Scholar

*Synopsis: istradefylline was proven safe and efficient in reducing off-time in Japanese PD patients with motor complications and on levodopa treatment.

Dungo R, Deeks ED. Istradefylline: first global approval. Drugs. 2013;73(8):875–882.
PubMed Web of Science ®Google Scholar

**Kyowa Hakko Kirin developed istradefylline as an A2A receptor antagonist for the treatment of PD, and the milestones in the process of its first world approval in Japan are presented.

Pinna A. Adenosine A2A receptor antagonists in Parkinson’s disease: progress in clinical trials from the newly approved istradefylline to drugs in early development and those already discontinued. CNS Drugs. 2014;28(5):455–474.
PubMed Web of Science ®Google Scholar
Jenner P. An overview of adenosine A2A receptor antagonists in Parkinson’s disease. Int Rev Neurobiol. 2014;119:71–86.
PubMed Web of Science ®Google Scholar
Hauser RA, Cantillon M, Pourcher E, et al. Preladenant in patients with Parkinson’s disease and motor fluctuations: a phase 2, double-blind, randomised trial. Lancet Neurol. 2011;10(3):221–229.
PubMed Web of Science ®Google Scholar
Merck. Merck provides update on phase III clinical program for preladenant, the company’s investigational Parkinson’s disease medicine. 2013 May 23. Available from: http://www.businesswire.com/news/home/20130523006358/en/Merck-Update-Phase-III-Clinical-Program-Preladenant#.VcZawPntmko.
Google Scholar
Hauser RA, Olanow CW, Kieburtz KD, et al. Tozadenant (SYN115) in patients with Parkinson’s disease who have motor fluctuations on levodopa: a phase 2b, double-blind, randomised trial. Lancet Neurol. 2014;13(8):767–776.
PubMed Web of Science ®Google Scholar
Perez-lloret S, Merello M. Two new adenosine receptor antagonists for the treatment of Parkinson’s disease: istradefylline versus tozadenant. Expert Opin Pharmacother. 2014;15(8):1097–1107.
PubMed Web of Science ®Google Scholar
Kondo T, Mizuno Y. A long-term study of istradefylline safety and efficacy in patients with Parkinson disease. Clin Neuropharmacol. 2015;38(2):41–46.
PubMed Web of Science ®Google Scholar

**Synopsis: In PD patients with wearing-off symptoms while on levodopa therapy, istradefylline consistently reduced off-time over a 52-week time period.

Chen W, Wang H, Wei H, et al. Istradefylline, an adenosine A₂A receptor antagonist, for patients with Parkinson’s Disease: a meta-analysis. J Neurol Sci. 2013;324(1–2):21–28.
PubMed Web of Science ®Google Scholar

**Synopsis: review on safety and efficacy of istradefylline that supports its safety and efficacy as adjunct therapy to levodopa in advanced PD patients.

Pierri M, Vaudano E, Sager T, et al. KW-6002 protects from MPTP induced dopaminergic toxicity in the mouse. Neuropharmacol. 2005;48(4):517–524.
PubMed Web of Science ®Google Scholar
Ikeda K, Kurokawa M, Aoyama S, et al. Neuroprotection by adenosine A2A receptor blockade in experimental models of Parkinson’s disease. J Neurochem. 2002;80(2):262–270.
PubMed Web of Science ®Google Scholar
Rao N, Uchimura T, Mori A. Evaluation of safety, tolerability, and multiple-dose pharmacokinetics of istradefylline in Parkinson’s disease patients [abstract no. PIII-88]. Clin Pharmacol Ther. 2008;83(Suppl 1):S99.
Google Scholar
Mizuno Y, Hasegawa K, Kondo T, et al. Clinical efficacy of istradefylline (KW-6002) in Parkinson’s disease: a randomized, controlled study. Mov Disord. 2010;25(10):1437–1443.
PubMed Web of Science ®Google Scholar
Bara-Jimenez W, Sherzai A, Dimitrova T, et al. Adenosine A(2A) receptor antagonist treatment of Parkinson’s disease. Neurology. 2003;61(3):293–296.
PubMed Web of Science ®Google Scholar
Hauser RA, Hubble JP, Truong DD. Randomized trial of the adenosine A(2A) receptor antagonist istradefylline in advanced PD. Neurology. 2003;61(3):297–303.
PubMed Web of Science ®Google Scholar
Stacy M, Silver D, Mendis T, et al. A 12-week, placebo-controlled study (6002-US-006) of istradefylline in Parkinson disease. Neurology. 2008;70(23):2233–2240.
PubMed Web of Science ®Google Scholar
Pourcher E, Fernandez HH, Stacy M, et al. Istradefylline for Parkinson’s disease patients experiencing motor fluctuations: results of the KW-6002-US-018 study. Parkinsonism Relat Disord. 2012;18(2):178–184.
PubMed Web of Science ®Google Scholar

*Synopsis: istradefylline significantly improved motor score at 40 mg/day, but did not impact the off-time.

Goetz CG, Wuu J, Mcdermott MP, et al. Placebo response in Parkinson’s disease: comparisons among 11 trials covering medical and surgical interventions. Mov Disord. 2008;23(5):690–699.
PubMed Web of Science ®Google Scholar
Kyowa Hakko Kogyo Co. Ltd. Results of phase-III clinical studies of an anti-Parkinson’s disease drug Istradefylline/KW-6002 conducted overseas [media release]. 2006 Mar 7. Available from: http://www.kyowa.co.jp.
Google Scholar
Kyowa Hakko Kirin Co. Ltd. Kyowa Hakko Kirin announces results of phase III clinical study of KW-6002 (istradefylline) for Parkinson’s disease in Japan [media release]. 2011 May 10. Available from: http://www.kyowa-kirin.co.jp.
Google Scholar
Zhu C, Wang G, Li J, et al. Adenosine A2A receptor antagonist istradefylline 20 versus 40 mg/day as augmentation for Parkinson’s disease: a meta-analysis. Neurol Res. 2014;36(11):1028–1034.
PubMed Web of Science ®Google Scholar
Tao Y, Liang G. Efficacy of adenosine A2A receptor antagonist istradefylline as augmentation for Parkinson’s disease: a meta-analysis of randomized controlled trials. Cell Biochem Biophys. 2015;71(1):57–62.
PubMed Web of Science ®Google Scholar
Matsuura K, Tomimoto H. Istradefylline is recommended for morning use: a report of 4 cases. Intern Med. 2015;54(5):509–511.
PubMed Web of Science ®Google Scholar
Factor S, Mark MH, Watts R, et al. A long-term study of istradefylline in subjects with fluctuating Parkinson’s disease. Parkinsonism Relat Disord. 2010;16(6):423–426.
PubMed Web of Science ®Google Scholar
Knebel W, Rao N, Uchimura T, et al. Population pharmacokinetic-pharmacodynamic analysis of istradefylline in patients with Parkinson disease. J Clin Pharmacol. 2012;52(10):1468–1481.
PubMed Web of Science ®Google Scholar
Müller T. The safety of istradefylline for the treatment of Parkinson’s disease. Expert Opin Drug Saf. 2015;14(5):769–775.
PubMed Web of Science ®Google Scholar
Nomoto M, Nagai M, Nishikawa N. Clinical nonmotor aspect of A2A antagonist in PD treatment. Int Rev Neurobiol. 2014;119:191–194.
PubMed Web of Science ®Google Scholar
Uchida S, Kadowaki-horita T, Kanda T. Effects of the adenosine A2A receptor antagonist on cognitive dysfunction in Parkinson’s disease. Int Rev Neurobiol. 2014;119:169–189.
PubMed Web of Science ®Google Scholar
Tombaugh TN. Trail Making Test A and B: normative data stratified by age and education. Arch Clin Neuropsychol. 2004;19(2):203–214.
PubMed Web of Science ®Google Scholar
Sandoval-Rincón M, Sáenz-farret M, Miguel-Puga A, et al. Rational pharmacological approaches for cognitive dysfunction and depression in Parkinson’s disease. Front Neurol. 2015;6:71.
PubMedGoogle Scholar
Hu X, Song X, Yuan Y, et al. Abnormal functional connectivity of the amygdala is associated with depression in Parkinson’s disease. Mov Disord. 2015;30(2):238–244.
PubMed Web of Science ®Google Scholar
El Yacoubi M, Ledent C, Parmentier M, et al. Adenosine A2A receptor antagonists are potential antidepressants: evidence based on pharmacology and A2A receptor knockout mice. Br J Pharmacol. 2001;134(1):68–77.
PubMed Web of Science ®Google Scholar
Yamada K, Kobayashi M, Shiozaki S, et al. Antidepressant activity of the adenosine A2A receptor antagonist, istradefylline (KW-6002) on learned helplessness in rats. Psychopharmacology (Berl). 2014;231(14):2839–2849.
PubMed Web of Science ®Google Scholar
Corsi C, Melani A, Bianchi L, et al. Striatal A2A adenosine receptor antagonism differentially modifies striatal glutamate outflow in vivo in young and aged rats. Neuroreport. 2000;11(11):2591–2595.
PubMed Web of Science ®Google Scholar
Kalda A, Yu L, Oztas E, et al. Novel neuroprotection by caffeine and adenosine A(2A) receptor antagonists in animal models of Parkinson’s disease. J Neurol Sci. 2006;248(1–2):9–15.
PubMed Web of Science ®Google Scholar
Chen JF, Xu K, Petzer JP, et al. Neuroprotection by caffeine and A(2A) adenosine receptor inactivation in a model of Parkinson’s disease. J Neurosci. 2001;21(10):RC143.
PubMed Web of Science ®Google Scholar
Yu L, Shen HY, Coelho JE, et al. Adenosine A2A receptor antagonists exert motor and neuroprotective effects by distinct cellular mechanisms. Ann Neurol. 2008;63(3):338–346.
PubMed Web of Science ®Google Scholar
Stocchi F, Rascol O, Kieburtz K, et al. Initiating levodopa/carbidopa therapy with and without entacapone in early Parkinson disease: the STRIDE-PD study. Ann Neurol. 2010;68(1):18–27.
PubMed Web of Science ®Google Scholar
Gyoneva S, Shapiro L, Lazo C, et al. Adenosine A2A receptor antagonism reverses inflammation-induced impairment of microglial process extension in a model of Parkinson’s disease. Neurobiol Dis. 2014;67:191–202.
PubMed Web of Science ®Google Scholar

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Share icon
Back to Top

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.

People also read
Recommended articles
Cited by

To cite this article:

Reference style: APA Chicago Harvard

Citation copied to clipboard

Reference styles above use APA (6th edition), Chicago (16th edition) & Harvard (10th edition)

Download citation

Download a citation file in RIS format that can be imported by citation management software including EndNote, ProCite, RefWorks and Reference Manager.

Choose format: RIS BibTex RefWorks Direct Export

Choose options: Citation Citation & abstract Citation & references

The efficacy of oral adenosine A_2A antagonist istradefylline for the treatment of moderate to severe Parkinson’s disease

References

*Synopsis: A phase 2 trial on the A2A receptor antagonist tozadenant shows similar efficacy as istradefylline and preladenant.

*Synopsis: The promising A2A receptor antagonist istradefylline was well tolerated and proven safe, and provided a clinically meaningful reduction of off-time in patients with advanced PD.

*Synopsis: Istradefylline as monotherapy for PD was proven safe and well tolerated, while statistical significance in improving motor control lacked in this study.

*Synopsis: Istradefylline as add-on therapy to a stable levodopa regimen significantly reduced the off-time in advanced stages of PD, while it is safe and well tolerated.

*Synopsis: istradefylline was proven safe and efficient in reducing off-time in Japanese PD patients with motor complications and on levodopa treatment.

**Kyowa Hakko Kirin developed istradefylline as an A2A receptor antagonist for the treatment of PD, and the milestones in the process of its first world approval in Japan are presented.

**Synopsis: In PD patients with wearing-off symptoms while on levodopa therapy, istradefylline consistently reduced off-time over a 52-week time period.

**Synopsis: review on safety and efficacy of istradefylline that supports its safety and efficacy as adjunct therapy to levodopa in advanced PD patients.

*Synopsis: istradefylline significantly improved motor score at 40 mg/day, but did not impact the off-time.

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

The efficacy of oral adenosine A2A antagonist istradefylline for the treatment of moderate to severe Parkinson’s disease

References

*Synopsis: A phase 2 trial on the A2A receptor antagonist tozadenant shows similar efficacy as istradefylline and preladenant.

*Synopsis: The promising A2A receptor antagonist istradefylline was well tolerated and proven safe, and provided a clinically meaningful reduction of off-time in patients with advanced PD.

*Synopsis: Istradefylline as monotherapy for PD was proven safe and well tolerated, while statistical significance in improving motor control lacked in this study.

*Synopsis: Istradefylline as add-on therapy to a stable levodopa regimen significantly reduced the off-time in advanced stages of PD, while it is safe and well tolerated.

*Synopsis: istradefylline was proven safe and efficient in reducing off-time in Japanese PD patients with motor complications and on levodopa treatment.

**Kyowa Hakko Kirin developed istradefylline as an A2A receptor antagonist for the treatment of PD, and the milestones in the process of its first world approval in Japan are presented.

**Synopsis: In PD patients with wearing-off symptoms while on levodopa therapy, istradefylline consistently reduced off-time over a 52-week time period.

**Synopsis: review on safety and efficacy of istradefylline that supports its safety and efficacy as adjunct therapy to levodopa in advanced PD patients.

*Synopsis: istradefylline significantly improved motor score at 40 mg/day, but did not impact the off-time.

Reprints and Corporate Permissions

Academic Permissions

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date

The efficacy of oral adenosine A_2A antagonist istradefylline for the treatment of moderate to severe Parkinson’s disease